Literature DB >> 3015184

Chemotherapy versus chemotherapy plus irradiation in limited small cell lung cancer. Results of a controlled trial with 5 years follow-up.

K Osterlind, H H Hansen, H S Hansen, P Dombernowsky, M Hansen, M Rørth.   

Abstract

One hundred and forty-five patients with limited stage small cell lung cancer were included in a randomized trial to evaluate the effect of chemotherapy with or without chest irradiation. Seventy-six patients were allotted chemotherapy alone while 69 patients received the same chemotherapy plus radiotherapy, 40 Gy in split-course, administered in weeks 6 and 10 after the initiation of chemotherapy. The chemotherapy consisted of lomustine, cyclophosphamide, vincristine and methotrexate. Patients treated with chemotherapy alone survived for a median of 52 weeks compared to 44 weeks in patients receiving the combined regimen (P = 0.055). After exclusion of five early deaths and one patient refusing the irradiation plus 14 completely resected patients, the remaining 65 patients receiving chemotherapy alone and the 60 patients treated with chemotherapy plus radiotherapy were included in a new analysis. The difference in survival duration which could be ascribed to treatment with or without chest irradiation thereby diminished (P = 0.24). Eighteen months' disease-free survival was obtained in 9.2% of the 65 patients and in 9.8% of the 60 patients. The complete remission rates were 37% and 46%, respectively, (P = 0.33) and the median durations of complete remission were 40 weeks and 52 weeks (P = 0.67). Treatment failure of the primary tumour occurred in 85% of patients treated with chemotherapy alone in contrast to 61% of patients receiving the combined regimen (P = 0.005). Seventy-nine of these patients underwent autopsy at which no residual chest disease was observed in 17% and 37%, respectively (P = 0.045). The combined regimen was more toxic than chemotherapy alone resulting in significantly greater dose reductions and more pronounced thrombocytopenia. Lung and pericardial fibrosis was responsible for four deaths among the complete responders in the radiotherapy group. The combined regimen thus tended to be more efficacious with respect to tumour control at the expense, however, of increased toxicity which per se, eliminated a potential improvement of the overall therapeutical results.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3015184      PMCID: PMC2001661          DOI: 10.1038/bjc.1986.146

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  15 in total

1.  Peritoneoscopy in the staging of 190 patients with small-cell anaplastic carcinoma of the lung with special reference to subtyping.

Authors:  P Dombernowsky; F Hirsch; H H Hansen; B Hainau
Journal:  Cancer       Date:  1978-05       Impact factor: 6.860

2.  A randomized study: small cell anaplastic lung cancer treated by combination chemotherapy and adjuvant radiotherapy.

Authors:  R M Fox; R L Woods; G N Brodie; M H Tattersall
Journal:  Int J Radiat Oncol Biol Phys       Date:  1980-08       Impact factor: 7.038

3.  Is thoracic radiation therapy necessary for patients with limited-stage small cell lung cancer? No.

Authors:  M H Cohen
Journal:  Cancer Treat Rep       Date:  1983-03

4.  Is chest radiotherapy necessary in any or all patients with small cell carcinoma of the lung? Yes.

Authors:  R W Byhardt; J D Cox
Journal:  Cancer Treat Rep       Date:  1983-03

5.  Radiotherapy in small cell cancer of the lung treated with combination chemotherapy: a controlled trial.

Authors:  R L Souhami; D M Geddes; S G Spiro; P G Harper; J S Tobias; B S Mantell; F Fearon; I Bradbury
Journal:  Br Med J (Clin Res Ed)       Date:  1984-06-02

6.  Long-term survival in small cell carcinoma of the lung.

Authors:  M Hansen; H H Hansen; P Dombernowsky
Journal:  JAMA       Date:  1980-07-18       Impact factor: 56.272

7.  Current status of research into small cell carcinoma of the lung: summary of the Second Workshop of the International Association for the Study of Lung Cancer (IASLC).

Authors:  J F Smyth; H H Hansen
Journal:  Eur J Cancer Clin Oncol       Date:  1985-11

8.  Small cell lung cancer: analysis of treatment factors contributing to prolonged survival.

Authors:  R Catane; A Lichter; Y J Lee; H D Brereton; J G Schwade; E Glatstein
Journal:  Cancer       Date:  1981-11-01       Impact factor: 6.860

9.  Radiotherapy of regional epidermoid carcinoma of the lung: a study in fractionation.

Authors:  R Sealy; S Lagakos; T Barkley; R Ryall; R D Tucker; R E Lee; G Ehlers
Journal:  Cancer       Date:  1982-04-01       Impact factor: 6.860

10.  Vindesine in the treatment of small cell anaplastic bronchogenic carcinoma.

Authors:  K Osterlind; P Dombernowsky; P G Sørensen; H H Hansen
Journal:  Cancer Treat Rep       Date:  1981 Mar-Apr
View more
  8 in total

Review 1.  Small cell lung cancer (SCLC): no treatment advances in recent years.

Authors:  Filippos Koinis; Athanasios Kotsakis; Vasileios Georgoulias
Journal:  Transl Lung Cancer Res       Date:  2016-02

2.  A meta-analysis of randomized controlled trials comparing early and late concurrent thoracic radiotherapy with etoposide and cisplatin/carboplatin chemotherapy for limited-disease small-cell lung cancer.

Authors:  Hongyang Lu; Luo Fang; Xiaojia Wang; Jufen Cai; Weimin Mao
Journal:  Mol Clin Oncol       Date:  2014-06-12

Review 3.  Lung cancer: a review of current therapeutic modalities.

Authors:  A B Sandler; A C Buzaid
Journal:  Lung       Date:  1992       Impact factor: 2.584

Review 4.  Therapeutic procedure in small cell lung cancer.

Authors:  Anastasios Kallianos; Aggeliki Rapti; Paul Zarogoulidis; Kosmas Tsakiridis; Andreas Mpakas; Nikolaos Katsikogiannis; Ioanna Kougioumtzi; Qiang Li; Haidong Huang; Bojan Zaric; Branislav Perin; Nikolaos Courcoutsakis; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2013-09       Impact factor: 2.895

5.  Detection of small cell lung cancer metastases in bone marrow aspirates using monoclonal antibody directed against neuroendocrine differentiation antigen.

Authors:  H H Berendsen; L de Leij; P E Postmus; J G Ter Haar; S Poppema; T H The
Journal:  J Clin Pathol       Date:  1988-03       Impact factor: 3.411

6.  Extracranial metastatic burden in extensive-stage small cell lung cancer: implications for prophylactic cranial irradiation.

Authors:  Daniel E Oliver; Olivia G Donnelly; G Daniel Grass; Arash O Naghavi; George Q Yang; Thomas J Dilling; Bradford A Perez
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

7.  Maintenance chemotherapy in limited small cell lung cancer: a randomised controlled clinical trial.

Authors:  M J Byrne; G van Hazel; J Trotter; F Cameron; J Shepherd; B Cassidy; V Gebski
Journal:  Br J Cancer       Date:  1989-09       Impact factor: 7.640

8.  Role of Chemoradiotherapy in Elderly Patients With Limited-Stage Small-Cell Lung Cancer.

Authors:  Christopher D Corso; Charles E Rutter; Henry S Park; Nataniel H Lester-Coll; Anthony W Kim; Lynn D Wilson; Zain A Husain; Rogerio C Lilenbaum; James B Yu; Roy H Decker
Journal:  J Clin Oncol       Date:  2015-10-19       Impact factor: 44.544

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.